Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
Dominick J. Angiolillo,Deepak L. Bhatt,Frank L. Lanza,Byron Cryer,Jin fei Dong,Walter Jeske,Ronald R. Zimmerman,Estela von Chong,Jayne Prats,Efthymios N. Deliargyris,Upendra Marathi +10 more
TL;DR: PL-ASA’s novel liquid formulation has similar PK and PD performance compared with IR-ASa, supporting functional and clinical equivalence, and it is suggested that this novel formulation may exhibit an improved benefit-risk profile, warranting evaluation in future trials.
Journal ArticleDOI
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.
Guillaume Marquis-Gravel,Matthew T. Roe,Matthew T. Roe,Robert A. Harrington,Daniel Muñoz,Adrian F. Hernandez,Adrian F. Hernandez,W. Schuyler Jones,W. Schuyler Jones +8 more
TL;DR: The role of aspirin for the primary prevention of cardiovascular diseases is revisited by critically reviewing the key scientific literature, highlight key areas of uncertainties for future research, and propose a decisional framework for clinicians to support prescription of aspirin in primary prevention.
Journal ArticleDOI
Helicobacter pylori infection and atherosclerosis: is there a causal relationship?
TL;DR: Assessment of current evidence for and against a causal relationship between H. pylori infection and atherosclerosis found that common risk factors shared by H. Pylori and their DNA in atherosclerotic plaques predestine their coexistence.
Journal ArticleDOI
Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin
Kathryn T. Hall,Thorsten Kessler,Julie E. Buring,Dani Passow,Howard D. Sesso,Robert Y. L. Zee,Paul M. Ridker,Daniel I. Chasman,Heribert Schunkert +8 more
TL;DR: In two randomized placebo-controlled trials in the setting of primary prevention, aspirin reduced the incidence of CVD events in individuals homozygous for the GUCY1A3 risk (G) allele, whereas heterozygote individuals had more events when taking aspirin.
Journal ArticleDOI
Vascular effects of nonsteroidal antiinflammatory drugs
Martin Soubrier,David Rosenbaum,Zuzana Tatar,Clément Lahaye,Jean-Jacques Dubost,Sylvain Mathieu +5 more
TL;DR: In patients with a history of coronary artery disease, diclofenac seems to carry the greatest risk, but all NSAIDs should be avoided, and an adverse effect of acetaminophen on the risk of cardiovascular disease cannot be completely ruled out.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.